What the research found

Michael Snyder and colleagues have demonstrated that continuous wearable monitoring can detect physiological shifts before symptoms appear—particularly for respiratory infections. Their work with Fitbit data during the pandemic showed presymptomatic detection of COVID-19, which has a longer asymptomatic window than influenza or other respiratory viruses. They've also identified incidental findings: wearables can flag atrial fibrillation with modest accuracy, and in one documented case, longitudinal wearable data showed a marked shift in resting heart rate and other parameters months before a cardiac event.

The research pivots on a foundational insight: wearables measure 24/7 against an individual's baseline. Because heart rate variability, blood oxygen, and resting heart rate follow predictable circadian patterns, deviations signal something is amiss. Snyder's team used this approach to provide early alerts to family members of immunocompromised patients, allowing isolation before exposure—a tangible clinical application.

Interestingly, the same biosignals that detect viral illness also flag psychological stress strongly, sometimes more so than infection. This overlap presents both a limitation and an opportunity: as data types from wearables expand beyond heart rate metrics, the potential to discriminate between physical and mental stressors should improve.

Why it matters for you

If you're already tracking resting heart rate and HRV on your wearable, you have the raw ingredients for baseline-deviation detection. The implication is simple: know your normal. When your resting heart rate drifts upward persistently, or your HRV drops, it often signals something—infection, overtraining, poor sleep, stress—before you feel symptomatic. This is especially relevant if you're managing training load or TRT cycles; both can shift cardiovascular metrics, so distinguishing a protocol effect from illness becomes actionable.

For users taking antivirals like Paxlovid or managing any acute illness, earlier detection (even by 24–48 hours) can matter. The same applies if you're around vulnerable people and want to quarantine before exposure occurs. More subtly, chronic elevation in resting heart rate or depressed HRV that doesn't improve with sleep and recovery might warrant investigating stress, metabolic dysfunction, or subclinical infection—all trackable via biomarkers you may already measure.

The caveats are important: wearables aren't diagnostic on their own, and their specificity varies. A red alert could be stress, illness, or noise. But as a screening layer that prompts further testing (rapid test, bloodwork) rather than clinical diagnosis, wearables fit naturally into a self-tracking protocol.

Caveats

• Detection accuracy varies: Atrial fibrillation detection operates at 30–50% sensitivity; no wearable is perfectly specific.
• Stress and infection overlap: Heart rate changes flag both, making discrimination difficult without additional data—this is partly unsolved.
• Not yet clinically integrated: Most standard healthcare systems don't yet act on wearable alerts; this remains a research and direct-to-consumer tool.
• Anecdotal evidence included: The cardiac case study is illustrative but not a systematic analysis; published peer-reviewed validation is limited compared to the scope of claims.
• Individual variation: Baselines and thresholds are personal; population-level norms may not apply to you.